Literature DB >> 11548884

Role of nitric oxide in regulation of coronary blood flow in response to increased metabolic demand in dogs with pacing-induced heart failure.

H Tada1, K Egashira, M Yamamoto, M Usui, Y Arai, Y Katsuda, H Shimokawa, A Takeshita.   

Abstract

The role of endothelium-derived nitric oxide (NO) in the metabolic control of coronary blood flow (CBF) in heart failure (HF) is poorly understood, so the present study investigated the effects of inhibitors of NO synthesis on the response of CBF to changes in myocardial oxygen consumption (MVO2) in dogs with HF produced by rapid ventricular pacing and in control dogs. The CBF, MVO2, and other hemodynamic parameters were measured in anesthetized animals. Before infusion of Nomega-nitro-L-arginine methyl ester (L-NAME), the increases in CBF and MVO2 during pacing tachycardia were not significantly different between the control and HF dogs. Intracoronary infusion of L-NAME did not alter the responses of CBF or MVO2 to pacing tachycardia in the control dogs, but in the HF dogs, it reduced the CBF response to pacing tachycardia without altering the tachycardia-induced changes in MVO2. Intracoronary infusion of L-arginine reversed the effect of L-NAME. These results suggest that in HF dogs NO contributes to the regulation of CBF in response to an increased metabolic demand.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11548884     DOI: 10.1253/jcj.65.827

Source DB:  PubMed          Journal:  Jpn Circ J        ISSN: 0047-1828


  2 in total

1.  Phosphodiesterase-5 activity exerts a coronary vasoconstrictor influence in awake swine that is mediated in part via an increase in endothelin production.

Authors:  Zhichao Zhou; Vincent J de Beer; Shawn B Bender; A H Jan Danser; Daphne Merkus; M Harold Laughlin; Dirk J Duncker
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-01-24       Impact factor: 4.733

Review 2.  Coronary blood flow in heart failure: cause, consequence and bystander.

Authors:  Gerd Heusch
Journal:  Basic Res Cardiol       Date:  2022-01-13       Impact factor: 12.416

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.